What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis

Francesco Passiglia, Massimo Cajozzo, Eugenio Fiorentino, Giuseppe Bronte, Antonio Russo, Ignacio Gil-Bazo, Antonio Russo, Francesco Passiglia, Eugenio Fiorentino, Patrick Pauwels, Christian Rolfo, Massimo Cajozzo, Jan P. Van Meerbeeck, Cosimo Lequaglie, Sergio Rizzo, Daniele Santini, Giuseppe Bronte, Christian Diego Rolfo, Sergio Rizzo

Risultato della ricerca: Articlepeer review

23 Citazioni (Scopus)


BackgroundRandomized phase III trials showed interesting, but conflicting results, regarding the treatment of NSCLC, PS2 population. This meta-analysis aims to review all randomized trials comparing platinum-based doublets and single-agents in NSCLC PS2 patients.Materials and methodsData from all published randomized trials, comparing efficacy and safety of platinum-based doublets to single agents in untreated NSCLC, PS2 patients, were collected. Pooled ORs were calculated for the 1-year Survival-Rate (1y-SR), Overall Response Rate (ORR), and grade 3–4 (G3–4) hematologic toxicities.ResultsSix eligible trials (741 patients) were selected. Pooled analysis showed a significant improvement in ORR (OR: 3.243; 95% CI: 1.883–5.583) and 1y-SR (OR: 1.743; 95% CI: 1.203–2.525) in favor of platinum-based doublets. G3–4 hematological toxicities were also more frequent in this group.ConclusionThis meta-analysis suggests that platinum-combination regimens are superior to singleagent both in terms of ORR and survival-rate with increase of severe hematological toxicities.
Lingua originaleEnglish
pagine (da-a)306-317
Numero di pagine12
Stato di pubblicazionePublished - 2015

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2720???
  • ???subjectarea.asjc.2700.2730???


Entra nei temi di ricerca di 'What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis'. Insieme formano una fingerprint unica.

Cita questo